MARKET

ONCT

ONCT

Oncternal Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.39
-0.60
-8.58%
After Hours: 6.41 +0.02 +0.31% 19:55 03/02 EST
OPEN
6.99
PREV CLOSE
6.99
HIGH
6.99
LOW
6.38
VOLUME
1.38M
TURNOVER
--
52 WEEK HIGH
8.65
52 WEEK LOW
1.490
MARKET CAP
311.85M
P/E (TTM)
-5.6176
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Oncternal Therapeutics to Participate in March Investor Conferences
- H.C. Wainwright: Global Life Sciences Conference -
GlobeNewswire · 6d ago
Northland Securities Issues a Buy Rating on Oncternal Therapeutics (ONCT)
In a report released yesterday, Carl Byrnes from Northland Securities assigned a Buy rating to Oncternal Therapeutics (ONCT), with a price target of
SmarterAnalyst · 6d ago
--Analyst Actions: Northland Starts Oncternal Therapeutics at Outperform With $21 Price Target
MT Newswires · 02/23 11:16
Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new non-executive employee, Christy Stolzer, who ...
GlobeNewswire · 02/23 04:04
Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb 22, 2021 (GLOBE NEWSWIRE via COMTEX) -- SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a...
GlobeNewswire · 02/22 22:34
The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17)
Benzinga · 02/18 13:14
The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 16)
Benzinga · 02/17 12:26
Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics
Zacks.com · 02/16 16:18
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONCT. Analyze the recent business situations of Oncternal Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ONCT stock price target is 14.50 with a high estimate of 21.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 75
Institutional Holdings: 8.45M
% Owned: 17.32%
Shares Outstanding: 48.80M
TypeInstitutionsShares
Increased
9
2.18M
New
40
2.45M
Decreased
3
426.15K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.09%
Pharmaceuticals & Medical Research
-0.90%
Key Executives
Chairman/Independent Director
David Hale
President/Chief Executive Officer/Director
James Breitmeyer
Chief Financial Officer/Treasurer/Secretary
Richard Vincent
Chief Scientific Officer
Gunnar Kaufmann
Other
Igor Bilinsky
Other
Frank Hsu
Director
Man Cho
Director
Rosemary Mazanet
Director
Robert Wills
Director
Nakanishi Xin
Independent Director
Michael Carter
Independent Director
Daniel Kisner
Independent Director
William LaRue
Independent Director
Charles Theuer
  • Dividends
  • Splits
  • Insider Activity
No Data
About ONCT
Oncternal Therapeutics, Inc., formerly GTX, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates for the treatment of cancers. Its pipeline includes cirmtuzumab, TK-216 and chimeric antigen receptor T-cell (CAR-T). Its cirmtuzumab product candidate is an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibody. Cirmtuzumab is in a Phase-I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). TK216 is a small-molecule compound designed to inhibit the biological activity of E26 transformation-specific (ETS) oncoproteins. TK216 is being evaluated in combination with vincristine in a Phase-I clinical trial in patients with relapsed or refractory Ewing sarcoma. Its CAR-T product candidate targets ROR-1 and is in preclinical development as a treatment for hematologic cancers and solid tumors.

Webull offers kinds of Oncternal Therapeutics Inc stock information, including NASDAQ:ONCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONCT stock methods without spending real money on the virtual paper trading platform.